|
|
|
|
|
Abciximab
drug data and news
Abciximab drug data, resources, and news articles (when available). Onconews.org provides news on cancer research. This section, which includes profiles on medicines that may or not be cancer-related is in beta form. If things run smoothly we will be releasing a new format late in the summer of 2006.
|
| Generic name | Abciximab | ||
| Brand Names/Synonyms | ReoPro; 7E3 antibody; antiGPIIBIIIa; ReoPro (Centocor) | ||
| Indication | For treatment of myocardial infarction, adjunct to percutaneous coronory intervention, unstable angina | ||
| Sponsored links | Description | Fab fragment of the chimeric human-murine monoclonal antibody 7E3. Abciximab binds to the glycoprotein (GP) lIb/IlIa receptor of human platelets and inhibits platelet aggregation. | |
| Pharmacology | Used for the treatment of myocardial infarction and the prevention of platelet aggregation. Abciximab inhibits platelet aggregation by preventing the binding of fibrinogen, von Willebrand factor, and other adhesive molecules to GPIIb/IIIa receptor sites on activated platelets. | ||
| Mechanism Of Action | Abciximab binds to the intact platelet GPIIb/IIIa receptor, which is a member of the integrin family of adhesion receptors and the major platelet surface receptor involved in platelet aggregation. This binding is thought to involve steric hindrance and/or conformational alterations which block access of large molecules to the receptor rather than direct interaction with the RGD (arginine-glycine-aspartic acid) binding site of GPlIb/IIIa. | ||
| Abciximab News (When available) |
ROSIE Trial Shows Abciximab May Be Most Effective Combined With ... Feb 21, 2006 Renewal of Mural Thrombus Releases Plasma Markers and Is Involved ... Feb 28, 2006 ASA: ReoPro-Retavase Duo Promising as Late Reperfusion Stroke ... Feb 20, 2006 Chairman of Cleveland Clinic Department of Cardiovascular Medicine ... Feb 9, 2006 Thrombolytic Treatment Before Stenting Linked to Increased ... Feb 14, 2006 | ||
| Dosage Forms | Not Available | ||
| Drug_Category | Anticoagulants; Antiplatelet Agents | ||
| Absorption | Not Available | ||
| Interactions | Not Available | ||
| Toxicity | Not Available | ||
| Organisms Affected | Humans and other mammals | ||
| Chemical IUPAC Name | Chimeric human-murine (anti CD41) 7E3 antibody. | ||
| Chemical Formula | C6462H9964N1690O2049S48 >1TXV:L ReoPro-like antibody Light Chain 1 >1TXV:H ReoPro-like antibody Heavy Chain 2 >1TXV:L ReoPro-like antibody Light Chain 2 | ||
| Molecular Weight | 145651.1 | ||
| Smiles String | Not Available | ||
| Melting Point | 61 oC (FAB fragment), 71 oC (whole mAb) - Vermeer, A.W.P. & Norde, W., Biophys. J. 78:394-404 (2000). | ||
| Water Solubility | Not Available | ||
| State | Transparent, slightly viscous, aqueous liquid | ||
| LogP/Hphobicity | -0.424 | ||
| Isoelectric Point | 6.16 | ||
| Biotransformation | Most likely removed by opsonization via the reticuloendothelial system when bound to platelets, or by human antimurine antibody production | ||
| Half Life | <10 min-30 min | ||
| Protein Binding [%] | Not Available | ||
| RxList Link | RXlist | ||
| Sponsored links | |||
| Drug Reference |
http://www.drugs.com/cons/Abciximab.html http://www.rxlist.com/cgi/generic2/abcixim.htm | ||
| Drug Type | Approved Drug | ||
| Accession No | BIOD00041 | ||
| CAS Registry Number | 143653-53-6 | ||
| KEGG Compound ID | Not Available | ||
| PubChem ID | Not Available | ||
| PharmGKB ID | PA448006 | ||
| SwissProt ID | Not Available | ||
| GenBank ID | Not Available | ||
| Drug ID Number [DIN] | Not Available |
|
Home | About | Cancers | Treatment | Medications Copyright onconews.org 2005. All Rights Reserved. |